Clearside Biomedical Inc

CLSDQ
$0.31 (- $0.03 - 8.82%)
Last updated: 2026-06-06 03:37 UTC
CLSDQ Metrics
Exchange
🇺🇸 NASDAQ XNGS
Nasdaq/NGS (Global Select Market)United StatesAmerica/New_York
SectorHealth Care
IndustryBiotechnology
ISINUS1850632035
CUSIP185063203
Market Price0.31
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPSN/A
Market Cap$1.3M
Book Value-10.31
Price to Book-0.024
BetaN/A
52w High8.7
52w Low0.01
Next Earnings DateN/A

Clearside Biomedical Inc trades under ticker CLSDQ on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Health Care exposure. Identifiers: ISIN US1850632035, CUSIP 185063203. Also searched as Clearside Biomedical.

Related researchCLSDQ stock priceCLSDQ share priceClearside Biomedical stockClearside Biomedical share price185063203
About the Company
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Price History